Table 2.
Common adverse events (≥10% of patients) during treatment and follow-up period
| Adverse event | PEG-IFN + RBV – 24 weeks (n = 90) | PEG-IFN + RBV – 48 weeks (n = 219) | Total (n = 309) |
|---|---|---|---|
| Headache | 38 (42.2) | 82 (37.4) | 120 (38.8) |
| Influenza like illness | 30 (33.3) | 72 (32.9) | 102 (33.0) |
| Fatigue | 26 (28.9) | 55 (25.1) | 81 (26.2) |
| Leucopenia | 18 (20.0) | 60 (27.4) | 78 (25.2) |
| Alopecia | 14 (15.6) | 57 (26.0) | 71 (23.0) |
| Depression | 19 (21.1) | 52 (23.7) | 71 (23.0) |
| Nausea | 17 (18.9) | 52 (23.7) | 69 (22.3) |
| Anemia | 8 (8.9) | 49 (22.4) | 57 (18.4) |
| Pyrexia | 17 (18.9) | 36 (16.4) | 53 (17.2) |
| Thrombocytopenia | 11 (12.2) | 42 (19.2) | 53 (17.2) |
| Pruritus | 12 (13.3) | 39 (17.8) | 51 (16.5) |
| Weight decreased | 12 (13.3) | 39 (17.8) | 51 (16.5) |
| Diarrhoea | 13 (14.4) | 35 (16.0) | 48 (15.5) |
| Influenza | 13 (14.4) | 30 (13.7) | 43 (13.9) |
| Arthralgia | 8 (8.9) | 33 (15.1) | 41 (13.3) |
| Myalgia | 11 (12.2) | 29 (13.2) | 40 (12.9) |
| Insomnia | 8 (8.9) | 31 (14.2) | 39 (12.6) |
| Asthenia | 10 (11.1) | 22 (10.0) | 32 (10.4) |
Values given in parentheses are percentages.